COSCIENS Biopharma Inc.
CSCI
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.57M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.57 Million |
|---|---|
| Enterprise Value | $1.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.93 |
| Beta | 1.85 |
| Outstanding Shares | 3,174,913 |
Return
| Return on Equity | -265.34% |
|---|---|
| Return on Assets | -68.33% |
| Return on Invested Capital | -80.46% |
Valuation & Multiples
| P/E Ratio | -1.09 |
|---|---|
| PEG | -1.21 |
| Price to Sales | 1.36 |
| Price to Book Ratio | 1.36 |
| Enterprise Value to Revenue | 0.19 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.42 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.12%▼ 0.73% |
|---|---|
| Total Invested | $10,306▼ 88.61% |
| Investors Holding | 2▼ 13.00% |
ESG Score
No data
About COSCIENS Biopharma Inc.
47 employees
CEO: Klaus Paulini æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez,...